Modified MMAF

CAT: 0804-HY-141594Size: 1 EachDry Ice: NoHazardous: No
CAT#: HY-141594Size: 1 Each
Selected
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Modified MMAF, an ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC) . Modified MMAF can be used for the targeted research of cancer[1].
CAS Number
[1352202-47-1]
UNSPSC
12352005
Target
Microtubule/Tubulin
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/modified-mmaf.html
Solubility
10 mM in DMSO
Smiles
O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@@H](NC)C(C)C)=O)=O)=O)OC)=O)CC3=CNC4=CC=CC=C34
Molecular Formula
C45H73N7O8
Molecular Weight
840.10
References & Citations
[1]Polson AG, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection [published correction appears in Cancer Res. 2010 Feb 1;70 (3) :1275. Slaga, Dion S [added]]. Cancer Res. 2009;69 (6) :2358-2364.|[2]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17 (1) :114-124.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported